Georges Karam, Sequans CEO, said, “We are nearing the October 9th deadline to increase our ADS price to meet the NYSE compliance obligations. This could be resolved organically after closing the ...
Johnson & Johnson reports positive results for Talvey in combination with Darzalex Faspro, pomalidomide and Tecvayli in the treatment of multiple myeloma. Read more here.